On 5/1/24, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a major increase of 10.7%, closing at $4.57. Moreover, this advance was accompanied by unusually high trading volume at 157% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 4.3% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment